ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

GETA is highlighted for its unique mechanism as a pan-PI3K/mTORC1/2 inhibitor ... whether it’s in HER2, Herceptin, PERJETA in the HER2 positive space or in HER2 in the overall space.

So for starters, I would say that the proportion of patients for whom the standard of care remains Herceptin chemo ... certainly an exciting new mechanism of action across these serious sleep ...

As with other molecularly targeted agents such as imatinib mesylate (Gleevec) and trastuzumab (Herceptin), the success ... Whatever the mechanism, activation of the PI3K pathway results in a ...

The vast majority of Roche’s oncology drugs with an orphan drug designation are expected to be blockbusters by 2025, including Perjeta (pertuzumab), Tecentriq (atezolizumab), Herceptin ...

Given its novel mechanism of action and proven efficacy, Herceptin was granted accelerated approval by the FDA in 1998. The dawn of the new millennium marked a paradigm shift in the way breast ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...

1 Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China 2 Department of Gastroenterology and Hepatology, Tianjin Second People’s Hospital, Tianjin, China The cancer-immunity ...